Tag Archive for: respiratory diseases

Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer

Vicore continues to strengthen its leadership in idiopathic pulmonary fibrosis (IPF) drug development by appointing Dr. Lindmark as its new Chief Medical Officer Lindmark brings deep expertise in late-stage clinical development for respiratory diseases, having developed Symbicort and several other global respiratory brands Appointment reflects Vicore’s advancement to late-stage development in IPF, following the interim […]

Vicore announces the appointment of Ahmed Mousa as CEO

Stockholm, July 13, 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) today announced that the Board of Directors has resolved to appoint Ahmed Mousa as new CEO of the Company with start in September 2023. This follows the July 5th announcement that Carl-Johan Dalsgaard plans to retire as CEO of the Company. […]

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the end of 2022 LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed patient enrollment with more than 800 subjects […]

Leading inhalation APIs expert Inke to triple production capacity

To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs Barcelona, Spain, April 20, 2022 – Inke, a leading global manufacturer of inhalation APIs wholly owned by Neuraxpharm Group, announces it is investing €9 million to increase […]

James Brady Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a Non-Executive Director. Read more…